Literature DB >> 18202688

Clinical pharmacology in the molecular era.

C T Dollery1.   

Abstract

The title of this article may raise a smile from colleagues in the field of basic pharmacology. To them, pharmacology has always been about molecular interactions, and this title may simply confirm a suspicion that clinical pharmacology is mainly about semi-quantitative observations that have only a limited foundation in hard science. They are partly right, at least regarding a communication problem. In a discussion about systems biology, an exasperated engineer once remarked that biologists and physicians do not even use the same routine software packages that engineers do. Similarly, a basic pharmacologist might note that, whereas he measures drug concentrations in micromoles, the clinical pharmacologist uses micrograms per milliliters. Nevertheless, as clinical pharmacologists seek to make more quantitative observations at the molecular level in living humans, our colleagues in basic pharmacology are delving into cellular signal transduction systems governed by complex protein-protein interactions and regulated by positive and negative feedback loops. In seeking to understand these systems, they face problems that are similar to the challenge of measurement in intact humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202688     DOI: 10.1038/sj.clpt.6100457

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

Review 1.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

2.  Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.

Authors:  Zvi Teitelbaum; Thierry Lave; Jan Freijer; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

3.  Molecular therapy drives patient-centric health care paradigms.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2010-08       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.